Bilirubin as a Biomarker in Liver Disease

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10329726" target="_blank" >RIV/00064165:_____/16:10329726 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10329726
Result on the web
<a href="http://link.springer.com/referenceworkentry/10.1007/978-94-007-7742-2_25-1" target="_blank" >http://link.springer.com/referenceworkentry/10.1007/978-94-007-7742-2_25-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/978-94-007-7742-2_25-1" target="_blank" >10.1007/978-94-007-7742-2_25-1</a>

Result language
angličtina
Original language name
Bilirubin as a Biomarker in Liver Disease
Original language description
Bilirubin had been studied since the eighteenth century because assessment of serum bilirubin concentration is important in the diagnosis and prognosis of patients with liver disorders. All prognostic scores for liver diseases include bilirubin in their calculations, and some studies have shown that bilirubin is an independent biomarker of mortality risk. We know that a high total bilirubin level is an indicator of disease, but nowadays there is evidence indicating the association of a low level with increased risk of diseases, for example, cancer or cardiovascular disorders. Bilirubin is a potential biomarker because its concentration is associated with mortality and may also be associated with the prevention of disease. This chapter will review the usefulness of bilirubin as a marker in liver diseases and their possible use to assess outcomes and risk of other non-liver diseases.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)